Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 37kWORD 17k
25 February 2020
E-004163/2019(ASW)
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-004163/2019

The Commission took note of the European Court of Auditors special report(1) and acknowledges the need to strengthen strategies for boosting Antimicrobial Resistance (AMR) research in the EU. The Commission is working towards the full implementation of the EU One Health Action Plan(2) against AMR(3), highlighted as a priority in the mission letter of the Commissioner for Health and Food Safety. In this context, it is important to boost the global dimension by advocating for a global agreement on the use of and access to antimicrobials(4).

As part of its actions against AMR, the Commission co-funds the development of new classes of antimicrobials via the Innovative Medicines Initiative’s ‘New Drugs 4 Bad Bugs’(5) and ‘AMR accelerator’(6) programmes. These partnerships between industry, academia and biotech organisations have invested more than EUR 950 million to bring new treatments and research incentives closer to patients.

The Commission together with the European Medicines Agency (EMA) has taken several actions to facilitate development of new antibiotics such as the EMA PRIME scheme(7) or an early engagement initiative with medicine developers through the EMA Innovation Task Force(8).

Moreover, the Commission supports global activities on AMR including the launch of a Global Antimicrobial Resistance Research and Development Hub in May 2018 after a call by G20 Leaders(9).

The Commission is exploring which further measures may be needed to boost development of new antimicrobials. In November 2019, a reflection on how to address market failures was started with Member States in the Commission’s Pharmaceutical Committee.

It is clear that significant progress in developing new classes of antimicrobials relies on the active involvement of all stakeholders.

(1)https://www.eca.europa.eu/en/Pages/DocItem.aspx?did=51992
(2)https://ec.europa.eu/health/sites/health/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf
(3)https://ec.europa.eu/health/amr/sites/amr/files/amr_2018-2022_actionplan_progressreport_en.pdf
(4)https://ec.europa.eu/commission/sites/beta-political/files/mission-letter-stella-kyriakides_en.pdf
(5)https://www.imi.europa.eu/projects-results/project-factsheets/nd4bb
(6)https://www.imi.europa.eu/projects-results/project-factsheets/nd4bb
celerator
(7) https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines
(8) https://www.ema.europa.eu/en/news/ema-facilitates-early-engagement-medicine-developers-combat-antimicrobial-resistance
(9)https://globalamrhub.org/
Last updated: 25 February 2020Legal notice - Privacy policy